Data show benefit of kidney cancer combo for patient subgroup

17 September 2021

From the 2021 annual congress of the European Society of Medical Oncology (ESMO), there is new data for a combo of Cabometyx (cabozantinib) and Opdivo (nivolumab) in the first-line treatment of renal cell carcinoma (RCC).

Cabometyx, a tyrosine kinase blocker, is developed by Exelixis (Nasdaq: EXEL), with rights outside the USA and Japan held by Ipsen (Euronext: IPN). Opdivo is a checkpoint blocker developed by Bristol Myers Squibb (NYSE: BMY).

While both are approved as monotherapy for later-line treatment of kidney cancer, the combination won approval for use as an initial treatment in the USA, Europe and Japan in the first part of 2021.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK